Jump to content

Cora Sternberg

From Wikipedia, the free encyclopedia
Cora Sternberg
Born
Philadelphia, Pennsylvania
Alma materUniversity of Pennsylvania
Sapienza University of Rome
AwardsOrder of Merit of the Italian Republic & others
Scientific career
FieldsOncology
InstitutionsWeill Cornell Medicine

Cora Sternberg is an American medical oncologist.

Sternberg previously served as chief of the medical oncology department at San Camillo-Forlanini Hospital in Rome, Italy, and adjunct professor at Sapienza University of Rome.[1][2] Sternberg is an elected board member of the European Organisation for Research and Treatment of Cancer (EORTC).[3]

She has been awarded the title ‘Grande Ufficiale al Merito della Repubblica Italiana’ and has received the Premio Minerva for Scientific Achievement, XVIII Edition for Achievements in Science.[4]

Biography[edit]

Born in Philadelphia, Sternberg earned her undergraduate degree at the College of Women at the University of Pennsylvania and her medical degree at the University of Pennsylvania in Philadelphia. She also obtained a second medical degree at the University of Rome La Sapienza.[5]

Upon transferring to Italy, Sternberg became a Consultant Physician at the Regina Elena Cancer Institute for Cancer Research, 1st Division of Medical Oncology in Rome, Italy. She then went on to become a Consultant Oncologist at the C.T.O. Hospital in Rome, Italy and subsequently Chief of the Department of Medical Oncology at the San Raffaele Scientific Institute in Rome, Italy and Consultant in Medical Oncology at the Regional General Hospital F. Miulli in Acquaviva delle Fonti, in Bari, Italy. From Fall 2002 - 2018 she was the Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy.[6] Since 2018, Dr. Cora Sternberg has been the Clinical Director of the Englander Institute for Precision Medicine and a full Professor at Weill Cornell in New York.

Honors and awards[edit]

References[edit]

  1. ^ Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID (April 2013). "A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update". European Journal of Cancer. 49 (6): 1287–1296. doi:10.1016/j.ejca.2012.12.010. PMID 23321547.
  2. ^ Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Lin SY, Penenberg D, Fair WR, Whitmore WF (15 December 1989). "Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse". Cancer. 64 (12): 2448–2458. doi:10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7. PMID 2819654.
  3. ^ "Dr. Cora Sternberg presented the long term results of EORTC trial 30994 at ASCO 2014 in Chicago". EORTC. 4 June 2014. Retrieved 20 January 2018.
  4. ^ "Oncologia. A Cora Sternberg il premio Esmo Award 2013 - Quotidiano Sanità". Quotidianosanita.it. Retrieved 20 January 2018.
  5. ^ McKillop, Christine (1 April 2007). "Interview with Dr Cora N. Sternberg: Prostate Cancer Chemotherapy". European Urology. 51 (4): 1136–1138. doi:10.1016/j.eururo.2007.01.037. PMID 17250951. Retrieved 20 January 2018.
  6. ^ "Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds". Prostate Cancer News Today. 12 September 2017. Retrieved 20 January 2018.
  7. ^ "A oncologa Cora Sternberg del Forlanini assegnato Esmo Award 2013". Pharmastar.it. Retrieved 20 January 2018.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cora_Sternberg&oldid=1233388203"